Overall, the present data, although circumstantial, emphasize the feasibility of developing multifunctional biocompatible uPAR-targeted nanoparticles as theranostic agents for combined diagnosis and image-guided therapy of uPAR-overexpressing primary and metastatic tumor lesions. The gene discussed is PLAUR; the disease is neoplasm.